Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus oral cyclophosphamide in platinum-resistant recurrent epithelial ovarian cancer
ChiCTR2100043955Phase 2Recruiting
- Sponsor
- Chen Jing
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and cyclophosphamide in epithelial ovarian cancer (EOC), sponsored by Chen Jing. Primary endpoints: Objective response rate, Progression-free survival time and 2 more. Started Mar 2021; status: recruiting.
02
Drugs
anlotinibcyclophosphamide
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on ChiCTR2100043955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043955.